| Name | Title | Contact Details |
|---|---|---|
Todd Morrow |
Chief Information Officer | Profile |
Todd Morrow |
President and Chief Information Officer | Profile |
Tyler Whatcott |
Chief Technology Officer | Profile |
Grove Hill Memorial Hospital Inc is a Grove Hill, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Microliter is a Cutchogue, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
WRKOUT is the future of fitness - delivering premium personal training LIVE to any device. No recorded content. No expensive equipment.
A regional leader in hospice and palliative care, Agape Care Group proudly serves more than 1,500 patients across South Carolina and Georgia. Agape Care South Carolina serves all 46 counties in the state and is also the only statewide palliative and hospice provider with a dedicated pediatric team through our Hands of Hope program. And in Georgia, we deliver care to 12 counties through our Augusta location, the cornerstone of the network we’re continuing to build. At Agape Care Group, we pride ourselves on our goal-oriented culture, dynamic leadership, and team-first attitude, and we’re committed to creating an inclusive, respectful workplace that reflects our core values. Our 900-plus employees are the heart of what we do, which is why we provide them with the resources and continuing education they need to excel. We strive to be an employer of choice in the health care industry, and we’re dedicated to building and maintaining an encouraging environment for our team members.
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.